New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease
Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2080 |
| _version_ | 1797232081231675392 |
|---|---|
| author | N. B. Perepech |
| author_facet | N. B. Perepech |
| author_sort | N. B. Perepech |
| collection | DOAJ |
| description | Resources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019). |
| first_indexed | 2024-03-08T14:00:57Z |
| format | Article |
| id | doaj.art-430f9754e8674ca88ffed6ff36181fe2 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:54:36Z |
| publishDate | 2020-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-430f9754e8674ca88ffed6ff36181fe22024-04-01T07:43:39ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-01-0115687388010.20996/1819-6446-2019-15-6-873-8801682New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart DiseaseN. B. Perepech0Saint-Petersburg State UniversityResources and methods for improving the prognosis in patients with chronic ischemic heart disease (IHD) are presented in the review. Information on the classes of drugs that improve the prognosis, and target values of the main physiological parameters that should be monitored during the treatment of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents and anticoagulants. The results of the most significant randomized clinical trials of the efficacy and safety of drugs from these classes in the treatment of chronic IHD are discussed. The results of the COMPASS study, which obtained confirmation of the positive effect of combined therapy with rivaroxaban and acetylsalicylic acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented in detail. The safety aspects of this therapy are discussed. The position of rivaroxaban in the treatment of patients with chronic IHD with sinus rhythm is presented according to the Recommendations of the European Society of Cardiology for the diagnosis and treatment of chronic IHD (2019).https://www.rpcardio.online/jour/article/view/2080chronic ischemic heart diseaseprognosisefficacy and safety of therapyantiplatelet agentsrivaroxaban |
| spellingShingle | N. B. Perepech New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease Рациональная фармакотерапия в кардиологии chronic ischemic heart disease prognosis efficacy and safety of therapy antiplatelet agents rivaroxaban |
| title | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease |
| title_full | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease |
| title_fullStr | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease |
| title_full_unstemmed | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease |
| title_short | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease |
| title_sort | new opportunities for improving the prognosis of patients with chronic ischemic heart disease |
| topic | chronic ischemic heart disease prognosis efficacy and safety of therapy antiplatelet agents rivaroxaban |
| url | https://www.rpcardio.online/jour/article/view/2080 |
| work_keys_str_mv | AT nbperepech newopportunitiesforimprovingtheprognosisofpatientswithchronicischemicheartdisease |